Abstract:ABSTRACT Epstein-Barr virus nuclear antigen (EBNA) leader protein (EBNALP) is one of the first viral genes expressed upon B-cell infection. EBNALP is essential for EBV-mediated B-cell immortalization. EBNALP is thought to function primarily by coactivating EBNA2-mediated transcription. Chromatin immune precipitation followed by deep sequencing (ChIP-seq) studies highlight that EBNALP frequently cooccupies DNA sites with host cell transcription factors (TFs), in particular, EP300, implicating a broader role in transcription regulation. In this study, we investigated the mechanisms of EBNALP transcription coactivation through EP300. EBNALP greatly enhanced EP300 transcription activation when EP300 was tethered to a promoter. EBNALP coimmunoprecipitated endogenous EP300 from lymphoblastoid cell lines (LCLs). EBNALP W repeat serine residues 34, 36, and 63 were required for EP300 association and coactivation. Deletion of the EP300 histone acetyltransferase (HAT) domain greatly reduced EBNALP coactivation and abolished the EBNALP association. An EP300 bromodomain inhibitor also abolished EBNALP coactivation and blocked the EP300 association with EBNALP. EBNALP sites cooccupied by EP300 had significantly higher ChIP-seq signals for sequence-specific TFs, including SPI1, RelA, EBF1, IRF4, BATF, and PAX5. EBNALP- and EP300-cooccurring sites also had much higher H3K4me1 and H3K27ac signals, indicative of activated enhancers. EBNALP-only sites had much higher signals for DNA looping factors, including CTCF and RAD21. EBNALP coactivated reporters under the control of NF-κB or SPI1. EP300 inhibition abolished EBNALP coactivation of these reporters. Clustered regularly interspaced short palindromic repeat interference targeting of EBNALP enhancer sites significantly reduced target gene expression, including that of EP300 itself. These data suggest a previously unrecognized mechanism by which EBNALP coactivates transcription through subverting of EP300 and thus affects the expression of LCL genes regulated by a broad range of host TFs. IMPORTANCE Epstein-Barr virus was the first human DNA tumor virus discovered over 50 years ago. EBV is causally linked to ∼200,000 human malignancies annually. These cancers include endemic Burkitt lymphoma, Hodgkin lymphoma, lymphoma/lymphoproliferative disease in transplant recipients or HIV-infected people, nasopharyngeal carcinoma, and ∼10% of gastric carcinoma cases. EBV-immortalized human B cells faithfully model key aspects of EBV lymphoproliferative diseases and are useful models of EBV oncogenesis. EBNALP is essential for EBV to transform B cells and transcriptionally coactivates EBNA2 by removing repressors from EBNA2-bound DNA sites. Here, we found that EBNALP can also modulate the activity of the key transcription activator EP300, an acetyltransferase that activates a broad range of transcription factors. Our data suggest that EBNALP regulates a much broader range of host genes than was previously appreciated. A small-molecule inhibitor of EP300 abolished EBNALP coactivation of multiple target genes. These findings suggest novel therapeutic approaches to control EBV-associated lymphoproliferative diseases.

Establishment of Bimolecular Complementation System for the Interaction Detection between Epstein-barr Virus Nuclear Antigen 1 and Host Proteins

A Protein-Protein Interaction Of Virus-Host Visualized By The Bimc Assay Technique

CONSTRUCTION OF THE BIMOLECULAR FLUORESCENCE COMPLEMENTATION ASSAY AND ITS APPLICATION FOR VIROLOGY

Expression and Purification of the DNA Binding Domain of the Epstein-Barr Virus Nuclear Antigen 1

Subcellular Localization of Epstein–Barr Virus BLLF2 and Its Underlying Mechanisms

Structure of Epstein-Barr Virus Tegument Protein Complex BBRF2-BSRF1 Reveals Its Potential Role in Viral Envelopment

Construction and expression of a spliced variant of Epstein-Barr virus bzlf1 and preparation of its polyclonal antibody.

A Background Assessable and Correctable Bimolecular Fluorescence Complementation System for Nanoscopic Single-Molecule Imaging of Intracellular Protein-Protein Interactions.

Lytic Replication and Inductive Production of Recombinant Epstein Barr Virus Visualized

Epstein-Barr Virus Episome Physically Interacts with Active Regions of the Host Genome in Lymphoblastoid Cells

Immunogenicity of A Multiepitope Plasmid Dna Encoding T and B Lymphocyte Epitopes from Latent Membrane Protein 2 (lmp2) of Epstein-Barr Virus As A Vaccine in Mice

Multiple cross displacement amplification combined with nanoparticle-based lateral flow biosensor for rapid and sensitive detection of Epstein-Barr virus

Prokaryotic Expression and Antigen Characteristics of EB Virus Latent Membrane Protein 2 ( EBV-LMP2) Multi-Epitopes

Immunization with Epstein–Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge

Establishment of Novel Monoclonal Fabs Specific for Epstein-Barr Virus Encoded Latent Membrane Protein 1

Nonmuscle Myosin Heavy Chain Iia Mediates Epstein-Barr Virus Infection of Nasopharyngeal Epithelial Cells

LEC-BiFC: a new method for rapid assay of protein interaction.

Nuclear Import of Epstein-Barr Virus BLLF2 is Mediated by an Importin Β1-Dependent Mechanism

Cloning And Expression Of Two Human Recombinant Monoclonal Fab Fragments Specific For Ebv Viral Capsid Antigen

Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300

Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion